Ion Exchange (India) Limited announced the approval of its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors reviewed and approved both standalone and consolidated results, along with the limited review report. The company also confirmed that these results are available on its website.
Board Approves Quarterly Financials
Ion Exchange (India) Limited has officially announced the outcome of its Board of Directors’ meeting held on August 5, 2026. During the meeting, the Board inter-alia considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended June 30, 2026. A copy of these results, accompanied by the Limited Review Report, has been enclosed with this disclosure.
Meeting Details and Information Availability
The Board of Directors’ meeting commenced at 02:00 p.m. and concluded at 06:00 p.m. on the same day. The company has further informed that the aforementioned financial information is publicly available on its official website, www.ionexchangeglobal.com, for stakeholders to access.
Financial Highlights (Unaudited Standalone Results – Quarter Ended June 30, 2026)
The presented unaudited standalone financial results for the quarter ended June 30, 2026, show a Profit after tax of INR 1,140 lacs. Total income for the quarter stood at INR 64,880 lacs, while total expenses were INR 63,343 lacs. The basic earnings per equity share (EPS) for the period were INR 0.927.
Financial Highlights (Unaudited Consolidated Results – Quarter Ended June 30, 2026)
For the consolidated results, the profit after tax for the quarter ended June 30, 2026, was INR 306 lacs. Total income for the consolidated entity was INR 70,641 lacs, with total expenses recorded at INR 69,942 lacs. The basic earnings per equity share (EPS) on a consolidated basis were INR 0.347.
Key Segment Performance (Standalone – Quarter Ended June 30, 2026)
In the standalone segment results, Treatment Solutions generated revenue from operations of INR 20,100 lacs, with a segment result of INR 1,826 lacs. Industrial Products reported revenue from operations of INR 10,553 lacs and a segment result of INR 1,366 lacs. Specialty Chemicals contributed INR 18,612 lacs in revenue from operations, with a segment result of INR 2,476 lacs.
Key Segment Performance (Consolidated – Quarter Ended June 30, 2026)
On a consolidated basis, Treatment Solutions recorded revenue from operations of INR 20,988 lacs, with a segment result of INR 1,735 lacs (loss). Industrial Products generated revenue from operations of INR 10,513 lacs and a segment result of INR 1,248 lacs. Specialty Chemicals reported revenue from operations of INR 22,965 lacs, with a segment result of INR 2,227 lacs.
Source: BSE
